MKI67 and neoplasm: Admittedly, the results from the second dataset of single agent everolimus alone are hard to interpret given that prognostic value of early Ki67 changes have only been shown for endocrine therapy and no clinical outcome data is currently available (ie no tumor shrinkage or relapse information).